IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan von Metz, Richard, Rust, Sonja, DuHadaway, James B., Mautino, Mario R., Munn, David H., Vahanian, Nicholas N., Link, Charles J., Prendergast, George C.

Volltext

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors von Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N, Jay Ramsey, W, Kennedy, Eugene, Mautino, Mario R, Link, Charles J, Lin, Ray S, Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M, Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H, Janik, John E, Khleif, Samir N

Volltext

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma von Zakharia, Yousef, McWilliams, Robert R, Rixe, Olivier, Drabick, Joseph, Shaheen, Montaser F, Grossmann, Kenneth F, Kolhe, Ravindra, Pacholczyk, Rafal, Sadek, Ramses, Tennant, Lucinda L, Smith, Christopher M, Kennedy, Eugene P, Link Jr, Charles J, Vahanian, Nicholas N, Yu, Jiayi, Shen, Steven S, Brincks, Erik L, Rossi, Gabriela R, Munn, David, Milhem, Mohammed

Volltext

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses von Chen, Wenlan Alex, Zhang, Jinjin, Hall, Katie M, Martin, Carol B, Kisselev, Serguei, Dasen, Emily J, Vahanian, Nicholas N, Link, Charles J, Martin, Brian K

Volltext

Pancreatic cancer: Update on immunotherapies and algenpantucel-L von McCormick, Kinsey A., Coveler, Andrew L., Rossi, Gabriela R., Vahanian, Nicholas N., Link, Charles, Chiorean, E. Gabriela

Volltext

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma von Zakharia, Y, Drabick, J, Khleif, S, Munn, D, Link, C, Vahanian, N, Kennedy, E, Rixe, O, Milhem, M

Volltext

A phase I study of indoximod in patients with advanced malignancies von Soliman, Hatem H, Minton, Susan E, Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A, Roberts, John D, Link, Charles, Vahanian, Nicholas N, Mautino, Mario, Streicher, Howard, Sullivan, Daniel M, Antonia, Scott J

Volltext

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors von Soliman, Hatem H, Jackson, Erica, Neuger, Tony, Dees, E Claire, Harvey, R Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N, Link, Charles, Sullivan, Daniel M, Antonia, Scott

Volltext

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer von WILDNER, O, MORRIS, J. C, VAHANIAN, N. N, FORD, H. JR, RAMSEY, W. J, BLAESE, R. M

Volltext

Hematopoietic Mixed Chimerism Derived from Allogeneic Embryonic Stem Cells Prevents Autoimmune Diabetes Mellitus in NOD Mice von Verda, Larissa, Kim, Duck An, Ikehara, Susumu, Statkute, Laisvyde, Bronesky, Delphine, Petrenko, Yevgeniya, Oyama, Yu, He, Xiang, Link, Charles, Vahanian, Nicholas N., Burt, Richard K.

Volltext

Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy von Johnson, Theodore S., Aguilera, Dolly, Al-Basheer, Ahmad, Castellino, Robert C., Eaton, Bree R., Esiashvili, Natia, Foreman, Nicholas, Heger, Ian M., Kennedy, Eugene P., Link, Charles J., Martin, William, Ring, Eric K., Sadek, Ramses F., Smith, Amy, Vahanian, Vahanian N., MacDonald, Tobey J., Munn, David H.

Volltext

346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors von Nayak, A, Hao, Z, Sadek, R, Dobbins, R, Marshall, L, Vahanian, N, Ramsey, J, Kennedy, E, Mautino, M, Link, C, Lin, R, Royer-Joo, S, Morrissey, K, Mahrus, S, McCall, B, Pirzkall, A, Munn, D, Janik, J, Khleif, S

Volltext

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens von Hemstreet, 3rd, George P, Rossi, Gabriela R, Pisarev, Vladimir M, Enke, Charles A, Helfner, Laura, Hauke, Ralph J, Tennant, Lucinda, Ramsey, William Jay, Vahanian, Nicholas N, Link, Charles J

Volltext

Algenpantucel-L immunotherapy in pancreatic adenocarcinoma von Coveler, Andrew L, Rossi, Gabriela R, Vahanian, Nicholas N, Link, Charles, Chiorean, E Gabriela

Volltext

A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge von Mandell, Robert B, Koukuntla, Ramesh, Mogler, Laura J.K, Carzoli, Andrea K, Freiberg, Alexander N, Holbrook, Michael R, Martin, Brian K, Staplin, William R, Vahanian, Nicholas N, Link, Charles J, Flick, Ramon

Volltext

αGal HyperAcute® Technology: Enhancing Immunogenicity of Antiviral Vaccines by Exploiting the Natural αGal-Mediated Zoonotic Blockade von Mandell, R.B, Flick, R, Staplin, W.R, Kaniewski, L.D, Carzoli, A.K, Manuszak, R.P, Wang, J, Rossi, G.R, Vahanian, N.N, Link, C.J

Volltext

Results of the NLG2105 Phase I Trial Using the IDO Pathway Inhibitor Indoximod, in Combination with Radiation and Chemotherapy, for Children with Newly Diagnosed DIPG von Johnson, T.S., Aguilera, D., Al-Basheer, A., Berrong, Z., Castellino, R.C., Eaton, B.R., Esiashvili, N., Foreman, N., Heger, I.M., Kennedy, E.P., Vahanian, N., Martin, W., Pacholczyk, R., Ring, E., Sadek, R.F., Smith, A., Shimoda, M., Macdonald, T.J., Munn, D.H.

Volltext

Abstract P2-11-09: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data von Tang, S-C, Montero, A, Munn, D, Link, C, Vahanian, N, Kennedy, E, Soliman, H

Volltext

A Phase 2 Study of Docetaxel in Combination with Indoximod for Metastatic Breast Cancer von Kennedy, E.P., Soliman, H.H., Ismail-Khan, R., Han, H., Rossi, G., Vahanian, N., Link, C., Sullivan, D., Antonia, S.

Volltext

Combination immunotherapy for high-risk resected and metastatic melanoma patients von Riker, Adam I, Rossi, Gabriela R, Masih, Prerna, Alsfeld, L C, Denham, Fiona, Tennant, Lucinda, Ramsey, W Jay, Vahanian, Nicholas N, Link, Charles J

Volltext